Back to Investors
bP

btov Partners

Venture Capital

btov Partners is a European venture capital firm focusing on technology startups since 2000, supported by a community of entrepreneurial private investors.

Portfolio

3

companies

AUM

£510M

under management


Portfolio companies

Chattermill

Chattermill

Chattermill offers a unified customer intelligence platform powered by deep learning artificial intelligence.

W

Weaver

Digital marketplace connecting architects and homeowners with general contractors for home renovations.

Healx

Healx

Healx deploys artificial intelligence to discover new therapies for rare conditions.


Team

FS

Florian Schweitzer

CEO and Partner


Recent investments

Series B
£21.3M

The Series B round was led by Beringea to support platform growth and expansion across the US and Europe.

"Customers today share vast amounts of feedback online across a wealth of platforms and channels, providing a huge opportunity for businesses to drive performance through customer insight. However, the current solutions in the market lack flexibility and accuracy when analysing this unstructured customer feedback across a wide range of sectors. Chattermill has, therefore, enabled a blue-chip roster of clients to tap into a ‘data gold mine’ that had previously been out of reach – the highly-scalable, intuitive product that Mikhail, Dmitry, and their exceptional team is demonstrating immense opportunity as proven by their rapid growth."
— Mark Shepherd, Investment Manager
Seed
£3.1M

The London-based marketplace secured backing from btov Partners to scale its digital renovation platform across the UK.

"We have been focused on building a platform for home renovation that not only serves an imminent need but will deliver even more value as we scale. Very few industries are as behind as the construction industry, and we are poised to become a game changer that can make home renovation much easier, less risky, and more cost-effective for contractors, architects and homeowners alike."
— Greg Keane, CEO
Series B
£43.9M

The financing round was led by Atomico with participation from several returning and new investors.

"The size of this Series B financing, especially this quickly after our Series A round last year, is an endorsement of the value of our platform and the pace at which we have developed. It allows us to scale our impact with the launch of our Rare Treatment Accelerator programme and to progress into clinical trials."
— Tim Guilliams, CEO